Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

exploratory · NOT_POSTED

Mutations in Deoxyribonucleic Acid (DNA) Homologous Repair Genes

Source null

→

exploratory · NOT_POSTED

Will assess if markers of angiogenesis in serial plasma samples are associated with response to cediranib alone or in combination with olaparib.

Source null

→

primary · POSTED

Progression-free survival is defined as the time from the date of study enrollment to the investigator-determined date of progression or death due to any cause, whichever occurs first. For individuals who are alive and progression-free, the censored time at risk will be defined as the time from the study enrollment date to the date of the patient's last radiographic disease assessment.

All patients randomized (Intent-to-Treat).

→

secondary · POSTED

Overall survival is defined as the time from the date of study enrollment to the date of death regardless of cause. For those individuals who have no death reported at the time of the analysis, the censored time at risk will be assessed from the date of study enrollment to the date that the patient was last contacted and known to be alive.

All patients randomized (Intent-to-Treat)

→

secondary · POSTED

Objective tumor response was assessed in patients with measurable disease by the site investigator using RECIST v1.1. Patients with complete or partial tumor response were considered to have a response.

All patients who are eligible for response assessment.

→

secondary · POSTED

The number of patients who reported at least a grade 3 adverse event were assessed in those who initiated treatment.

Patients who initiated assigned treatment.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-endometrial-cancer-keytruda-qlex-1191efca
nct id: NCT03660826
trial label: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following
applicability: unclear
applicability note: Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 7
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0004
source section id
NCT03660826-om-0004
source outcome index
4
endpoint
Mutations in Deoxyribonucleic Acid (DNA) Homologous Repair Genes
endpoint definition
Mutations in Deoxyribonucleic Acid (DNA) Homologous Repair Genes
time origin
Up to 5 years
analysis role
exploratory
reporting status
NOT_POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0005
source section id
NCT03660826-om-0005
source outcome index
5
endpoint
Markers of Angiogenesis in Serial Plasma Samples
endpoint definition
Will assess if markers of angiogenesis in serial plasma samples are associated with response to cediranib alone or in combination with olaparib.
time origin
Up to 5 years
analysis role
exploratory
reporting status
NOT_POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
source section id
NCT03660826-om-0000
source outcome index
0
endpoint
Progression-free Survival
endpoint definition
Progression-free survival is defined as the time from the date of study enrollment to the investigator-determined date of progression or death due to any cause, whichever occurs first. For individuals who are alive and progression-free, the censored time at risk will be defined as the time from the study enrollment date to the date of the patient's last radiographic disease assessment.
time origin
Scans were done every 8 weeks for the first year and then every 12 weeks thereafter until disease progression. Vital status was assessed every 3 months for 2 years and then every 6 months for 3 years (5-years total).
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
All patients randomized (Intent-to-Treat).
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0001
source section id
NCT03660826-om-0001
source outcome index
1
endpoint
Overall Survival
endpoint definition
Overall survival is defined as the time from the date of study enrollment to the date of death regardless of cause. For those individuals who have no death reported at the time of the analysis, the censored time at risk will be assessed from the date of study enrollment to the date that the patient was last contacted and known to be alive.
time origin
Vital status was assessed every 3 months for 2 years and then every 6 months for 3 years (5-years total).
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All patients randomized (Intent-to-Treat)
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0002
source section id
NCT03660826-om-0002
source outcome index
2
endpoint
Objective Tumor Response
endpoint definition
Objective tumor response was assessed in patients with measurable disease by the site investigator using RECIST v1.1. Patients with complete or partial tumor response were considered to have a response.
time origin
Scans were done every 8 weeks for the first year; then every 12 weeks thereafter until disease progression is confirmed or up to 33 months.
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All patients who are eligible for response assessment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0003
source section id
NCT03660826-om-0003
source outcome index
3
endpoint
Incidence of Adverse Events
endpoint definition
The number of patients who reported at least a grade 3 adverse event were assessed in those who initiated treatment.
time origin
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy up to 50 months.
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Patients who initiated assigned treatment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG000
arm label
Arm I (Cediranib maleate_Reference Group 1)
regimen
Patients randomized to Cedinarib reference arm during the recruitment period (09/04/2018-06/17/2019). Patients receive Cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Cediranib: Given PO Cediranib Maleate: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG001
arm label
Arm II (Olaparib)
regimen
Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG002
arm label
Arm III (Cediranib Maleate, Olaparib)
regimen
Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Cediranib: Given PO Cediranib Maleate: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG003
arm label
Arm IV (Olaparib, Capivasertib)
regimen
Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Capivasertib: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG004
arm label
Arm V (Olaparib, Durvalumab)
regimen
Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Computed Tomography: Undergo CT scan Durvalumab: Given IV Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG005
arm label
Arm VI (Cediranib Maleate, Durvalumab)
regimen
Patients receive cediranib maleate PO QD on days 1-5 each week and durvalumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Cediranib Maleate: Given PO Computed Tomography: Undergo CT scan Durvalumab: Given IV Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA
analyzed count
43
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG005
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0000
arm key
OG006
arm label
Arm VII (Cediranib maleate_Reference Group 2)
regimen
Patients randomized to Cedinarib reference arm during the recruitment period (08/16/2021-06/28/2023). Patients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Cediranib: Given PO Cediranib Maleate: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA
analyzed count
41
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0000#groups/OG006
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0001
arm key
OG000
arm label
Arm I (Cediranib maleate_Referenc Group 1)
regimen
Patients randomized to Cedinarib reference arm during the recruitment period (09/04/2018-06/17/2019). Patients receive Cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Cediranib: Given PO Cediranib Maleate: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0001
arm key
OG001
arm label
Arm II (Olaparib)
regimen
Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0001
arm key
OG002
arm label
Arm III (Cediranib Maleate, Olaparib)
regimen
Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Cediranib: Given PO Cediranib Maleate: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0001#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0001
arm key
OG003
arm label
Arm IV (Olaparib, Capivasertib)
regimen
Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Capivasertib: Given PO Computed Tomography: Undergo CT scan Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0001#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
outcome key
om-0001
arm key
OG004
arm label
Arm V (Olaparib, Durvalumab)
regimen
Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study. Biospecimen Collection: Undergo blood sample collection Bone Marrow Aspirate: Undergo bone marrow aspiration and biopsy Bone Marrow Biopsy: Undergo bone marrow aspiration and biopsy Computed Tomography: Undergo CT scan Durvalumab: Given IV Echocardiography: Undergo Echo Multigated Acquisition Scan: Undergo MUGA Olaparib: Given PO
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03660826-om-0001#groups/OG004

harms

release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG000
source section id
NCT03660826-ae
event group key
EG000
event group label
Arm I (Cediranib maleate_Reference Group 1)
serious affected
17
serious at risk
39
other affected
38
other at risk
39
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG001
source section id
NCT03660826-ae
event group key
EG001
event group label
Arm II (Olaparib)
serious affected
12
serious at risk
40
other affected
40
other at risk
40
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG002
source section id
NCT03660826-ae
event group key
EG002
event group label
Arm III (Cediranib Maleate, Olaparib)
serious affected
19
serious at risk
39
other affected
39
other at risk
39
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG003
source section id
NCT03660826-ae
event group key
EG003
event group label
Arm IV (Olaparib, Capivasertib)
serious affected
11
serious at risk
42
other affected
41
other at risk
42
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG004
source section id
NCT03660826-ae
event group key
EG004
event group label
Arm V (Olaparib, Durvalumab)
serious affected
16
serious at risk
42
other affected
42
other at risk
42
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG005
source section id
NCT03660826-ae
event group key
EG005
event group label
Arm VI (Cediranib Maleate, Durvalumab)
serious affected
13
serious at risk
42
other affected
40
other at risk
42
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-endometrial-cancer-keytruda-qlex-1191efca
nct id
NCT03660826
harm key
EG006
source section id
NCT03660826-ae
event group key
EG006
event group label
Arm VII (Cediranib maleate_Reference Group 2)
serious affected
19
serious at risk
37
other affected
37
other at risk
37
frequency threshold
0
collection period
Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy. Median follow-up was 22 months.
event definition
Patients randomized were included for the all-cause mortality summary. Patients randomized and also initiated treatment were included for the AE/SAE summary.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice